pyridinolcarbamate has been researched along with Glomerulosclerosis, Focal Segmental in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Glomerulosclerosis, Focal Segmental: A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oppermann, W | 1 |
| Reddi, AS | 1 |
| Velasco, CA | 1 |
| Davalos, RA | 1 |
1 other study available for pyridinolcarbamate and Glomerulosclerosis, Focal Segmental
| Article | Year |
|---|---|
Attempts to delay the progression of inherited vasculopathy.
Topics: Animals; Basement Membrane; Glomerulosclerosis, Focal Segmental; Glucose Tolerance Test; Glycoprotei | 1976 |